The FDA has begun soliciting feedback to inform the next version of the Prescription Drug User Fee Act. User fees remain ...

MASLD has become the most common chronic liver disease worldwide. The authors review the features of the disease as well as pharmacotherapies targeting the associated liver and cardiovascular ...

Risdiplam, an oral pre–messenger RNA splicing modifier, is an efficacious treatment for persons with symptomatic spinal muscular atrophy (SMA). The safety and efficacy of risdiplam in ...

A 28-year-old woman was admitted to the hospital because of severe hypoxemia and right heart failure that had been caused by rapidly progressive pulmonary hypertension. A diagnosis was made.

Semaglutide and cagrilintide have each been shown to induce weight loss, but how these drugs work in combination in patients with type 2 diabetes and overweight or obesity is unknown. New research ...

Though infant mortality has continuously been targeted by health policy agendas, policies tend to place it in an individualistic and narrow frame, failing to consider and address its structural ...

Quick Take Video Summary from The New England Journal of Medicine — Cagrilintide–Semaglutide in Adults with Overweight or Obesity ...

In this cluster-randomized, crossover trial, hospital-wide use of lactated Ringer’s solution as compared with normal saline did not alter the incidence of death or hospital readmission within 90 ...

Whether lactated Ringer’s solution is clinically superior to normal saline for routine intravenous administration of fluids to hospitalized patients is unclear. New research findings are ...

In this phase 3a trial involving adults with obesity and diabetes, the use of cagrilintide–semaglutide resulted in a significantly lower body weight than placebo at 68 weeks.